Cure8 research brief
A sizable minority of people newly diagnosed with IBD—about 1 in 5 with Crohn’s and 1 in 10 with ulcerative colitis—received no IBD-specific drugs within the first year. Understanding who is untreated and why could affect monitoring, follow-up plans, and research priorities.
Newly diagnosed patients with Crohn’s disease or ulcerative colitis (including older adults), caregivers, gastroenterology clinicians, and researchers studying treatment patterns and health services.
This study uses national prescription and health registries to identify treatment patterns after diagnosis; it reports proportions and calendar-period trends rather than causes or outcomes.
The article highlights a substantial subgroup of patients who are pharmacologically untreated early after diagnosis and suggests the need for further research into why—possible explanations could include mild disease, watchful waiting, patient preference, comorbidity, or gaps in care, but the registry data do not by themselves determine the reasons.
Practical note: The paper describes patterns in Denmark’s healthcare registries and does not provide individual-level clinical decision guidance. Clinicians and patients should interpret the findings as descriptive registry evidence that identifies groups for further study rather than prescriptive treatment recommendations.
This is an observational registry study from Denmark covering 1996–2020; it reports treatment uptake and temporal trends but does not report reasons for non-treatment or long-term clinical outcomes. Findings may reflect Danish practice patterns and registry capture of prescriptions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The review highlights that colorectal IBD is under-recognized and often mistaken for infectious colitis in sub‑Saharan Africa due to limited diagnostic and specialist resources, which can delay appropriate care.
IBD-U means no clear Crohn’s or ulcerative colitis diagnosis yet — that uncertainty can affect treatment decisions and follow-up. The review highlights tests that may help clarify diagnosis and stresses that many...
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
